Contrast agent manufacturer Guerbet had a banner year in 2011, with sales of 378 million euros and net income of 14.4 million euros, representing a revenue increase of 7.2% and a net income increase of 145.4% from 2010.
In 2010, Guerbet had sales of 352.6 million euros, and net income of 5.9 million euros.
The Villepinte, France-headquartered company attributed much of this financial achievement to its MRI contrast agent Dotarem. Dotarem attained a 4 percentage point market share increase in 2011, to reach a market share of 45% in Europe. Sales of this product in the global market increased by 12.8% for the year.
Sales of x-ray imaging agent Xenetix expanded 5% during 2011, with 9.1% growth in the fourth quarter. This was primarily due to a sales increase of 22.1% for the year in China, South Korea, and Mexico, offsetting a 2.5% sales reduction in Europe.
Guerbet also reported that sales surged by 56.4% for Lipiodol, a product used largely for interventional radiology. The growth was attributed to sales in North America and Latin America during the first quarter.
